Search Results
Your search for all items matches 35432 pages
Showing 18001 - 18050Bleomycin-Related Toxicity and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors
In a retrospective single-institution analysis reported in the Journal of Clinical Oncology, Calaway et al found that the addition of bleomycin to etoposide/cisplatin did not appear to increase risk of pulmonary or postoperative morbidity after postchemotherapy retroperitoneal lymph node dissection ...
Danish Study on Effect of Screening on Breast Cancer Mortality
In a Danish study reported in the Journal of Clinical Oncology, Beau et al used different models to assess the effects of screening on breast cancer mortality, finding a 20% reduction among patients diagnosed during the recommended screening age range. As noted by the investigators, the study was...
Rituximab/Lenalidomide vs Rituximab/Chemotherapy in Advanced Untreated Follicular Lymphoma
In a phase III RELEVANCE trial reported in The New England Journal of Medicine by Morschhauser et al, no difference in complete response rate or interim progression-free survival was found between rituximab [Rituxan]/lenalidomide [Revlimid] vs rituximab/chemotherapy in newly diagnosed advanced...
6th Annual Rally for Medical Research Hill Day Advocates for Continued Growth in Federal Funding for the NIH
Nearly 350 organizations—including medical societies and oncology treatments centers—are advocating for robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH) during the 6th annual Rally for Medical Research Hill Day, taking place...
Bleeding in Patients Treated With Anticoagulants and Potential Cancers
Bleeding in patients treated with anticoagulants may indicate an increased probability of cancer, according to late-breaking results from the COMPASS trial presented at the 2018 European Society of Cardiology Congress. Principal investigator John Eikelboom, MD, of the Population Health Research...
Study Finds Hispanic Pediatric Patients at Increased Risk of Methotrexate Neurotoxicity During Treatment for ALL
Case studies have reported a high prevalence of methotrexate subacute neurotoxicity among Hispanic adolescents with acute lymphoblastic leukemia (ALL), suggesting sensitivity to methotrexate therapy may differ by race and ethnicity. Now, a prospective study in pediatric patients with ALL has found...
10-Year Follow-up of Axillary Dissection vs No Dissection in Breast Cancer With Sentinel Node Micrometastases
In the 10-year follow-up of the phase III International Breast Cancer Study Group (IBCSG) 23-01 trial reported in The Lancet Oncology, Galimberti et al found no significant difference in disease-free survival with axillary dissection vs no axillary dissection in patients with breast cancer and...
Sequential Brentuximab Vedotin and AVD in Older Patients With Newly Diagnosed Hodgkin Lymphoma
In a phase II study reported in the Journal of Clinical Oncology, Evens et al found that a regimen of brentuximab vedotin (Adcetris) given sequentially before and after standard doxorubicin, vinblastine, and dacarbazine (AVD) was associated with good outcomes in untreated older patients with...
Lasker Foundation Announces 2018 Lasker Awards for Basic and Clinical Medical Research and Special Achievement
The Albert and Mary Lasker Foundation today announced the winners of its 2018 Lasker Awards: C. David Allis, PhD, of Rockefeller University and Michael Grunstein, PhD, of the University of California, Los Angeles, will receive the Albert Lasker Basic Medical Research...
Somatic Mutations in ER-Positive Breast Cancer and Prognosis
Recent research and genomic studies have revealed a number of genes that accumulate somatic mutations and alterations in estrogen receptor (ER)–positive breast cancer. However, while a few alterations are quite common and relatively well-understood, many genes are mutated in less than 5% of...
Small Study Shows Chemotherapy May Lead to Early Menopause in Young Women With Lung Cancer
A new study suggests chemotherapy may cause acute amenorrhea, leading to early menopause in women with lung cancer. The study is the first to comment on amenorrhea rates in women younger than 50, concluding that women with lung cancer who desire future fertility should be educated about risks and...
Outcomes With Station 4L Lymph Node Dissection in Left Lung Cancer
In a Chinese single-institution study reported in the Journal of Clinical Oncology, Wang et al found that station 4L lymph node (LN) dissection was associated with improved outcome in patients with primary cancer of the left lung. Study Details The retrospective analysis included 657 patients...
ASCO/IDSA Clinical Practice Guideline Update: Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
As reported in the Journal of Clinical Oncology by Randy A. Taplitz, MD, of UC San Diego Health, and colleagues, ASCO and the Infectious Diseases Society of America (IDSA) have updated their joint guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with...
ASCO Answers Palliative Care: A Resource for Your Patients
THE ASCO ANSWERS Palliative Care booklet shares how palliative care or supportive care is used to manage symptoms and side effects; help with practical concerns; address spiritual questions; and support caregivers, family, and friends. Your patients will find: Practical advice on how to access...
ASCO Volunteer Advocates Bringing Cancer Priorities to Capitol Hill for 2018 Advocacy Summit
ON SEPTEMBER 25–26, oncology care providers from across the United States will head to Capitol Hill to participate in the 3rd annual ASCO Advocacy Summit. Over 2 days, ASCO volunteer advocates will meet with members of Congress and their staff to educate them on critical issues affecting patients...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
HOW DO patients really feel when they are in your care? What does it feel like to cure a cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? They are the personal topics explored in the candid and inspirational mini-podcast series, Your Stories:...
Applying for a Conquer Cancer Research Grant: Tips From Past YIA and CDA Recipients
Research grants are vital to the success of academic research and researchers apply for these grants at all stages of their career. This makes writing stand-out grant applications an incredibly valuable skill for clinical investigators—and an intimidating task for first-time grant applicants....
Cory Wiegert Named New CEO of CancerLinQ LLC
Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO. Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, began his new role on August 13, 2018, and is overseeing the continued...
Becoming a Leader in Oncology With ASCO’s Leadership Development Program
ASCO offers a portfolio of prestigious leadership training opportunities for those who are ready to take the next step in their careers. This includes the Leadership Development Program (LDP), a program that began in 2009 and was created to teach mid-career oncologists leadership skills and help...
Actively Recruiting Clinical Trials Focused on Thyroid Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on targeted therapy in thyroid cancer. These trials are studying immunosuppressants, combination therapies, tyrosine kinase inhibitor treatment, mitigation of treatment side...
Lung Cancer Expert Leora Horn, MD, Recalls Her Journey to a Career in Oncology and a Home in Nashville
The tumultuous history of modern South Africa has numerous stories that lie beneath the surface of the sociopolitical headlines, such as the story of lung cancer expert Leora Horn, MD. “I was born and reared in Johannesburg, South Africa, a second-generation African family. In 1987, because of the...
Georgetown Launches Open Access Brain Cancer Biomedical Database
THE GEORGETOWN Lombardi Comprehensive Cancer Center has developed and released a cache of brain cancer biomedical data and made them freely available to researchers worldwide. The database, referred to as REMBRANDT (Repository for Molecular Brain Neoplasia Data), contains information on 671 adult...
Male Breast Cancer: An Understudied Malignancy
Male breast cancer is a rare and understudied malignancy when compared with female breast cancer, with conflicting literature on survival outcomes in men and women. The ASCO Post spoke recently with breast cancer expert Sharon Giordano, MD, MPH, FASCO, Professor at The University of Texas MD...
Expanding the Use of Provider Orders for Life-Sustaining Treatment for Patients With Advanced Cancer
Patients with advanced cancer often get more aggressive treatment than they want because too few oncologists elicit their end-of-life treatment preferences.1,2 In response to this problem, leading associations, including ASCO3,4 and the Institute of Medicine,5 have called for more advance care...
Brian C. Capell, MD, PhD, Receives Award for Skin Cancer Research
BRIAN C. CAPELL, MD, PhD, Assistant Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, has received a Damon Runyon Clinical Investigator Award. He plans to use the $450,000 research grant to study epigenetic targets in the skin to develop more effective...
2019 Pershing Square Sohn Cancer Research Prize Is Opening for Applications on October 1, 2018
THE PERSHING Square Sohn Cancer Research Alliance will open for applications for its 2019 Pershing Square Sohn Prize for Young Investigators in Cancer Research on October 1, 2018. At least six New York City area–based scientists will each be awarded $200,000 per year for up to 3 years. Applicants...
Ana María López, MD, MPH, Becomes Chief of Cancer Services at Sidney Kimmel
ANA MARÍA LÓPEZ, MD, MPH, has joined the Sidney Kimmel Cancer Center (Sidney Kimmel), Jefferson Health, as Vice Chair of Medical Oncology and Chief of Cancer Services. Dr. López brings her expertise in breast and gynecologic cancers, integrative medicine, telehealth, and cancer disparities with...
Challenges of Managing Older Patients With Diffuse Large B-Cell Lymphoma
As the population continues to age, the interplay between aging and cancer increasingly shows cancer to be a disease of older people. By the year 2030, there will be an increased incidence of non-Hodgkin lymphoma (NHL) in older individuals.1 The median age of patients diagnosed with diffuse large...
Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?
USING THE National Cancer Database, Bhatt et al1 recently reported that of the 61,775 adults with acute myeloid leukemia (AML), those who received chemotherapy from 2003 to 2011 lived longer than those who, in those same years, did not; the study is reviewed in this issue of The ASCO Post....
Suboptimal Use of Initial Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia
IN A STUDY of National Cancer Database data reported in Blood Advances, Vijaya Raj Bhatt, MD, of the University of Nebraska Medical Center, and colleagues found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that...
Three Immunotherapy Researchers Receive 2018 Albany Medical Center Prize
THREE SCIENTISTS whose work in immuno-oncology has led to a revolutionary way to treat cancer have been announced as the recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research. The awardees were chosen to receive the 2018 Albany Prize for their research in...
Expert Point of View: Ian Olver, MD, PhD
COMMENTING ON the importance of this topic at a press conference during the 2018 Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting, Ian Olver, MD, PhD, Immediate Past President of MASCC and Director of the University of...
Cardiac Issues Related to Checkpoint Inhibitors Still Largely Understudied
IMMUNE CHECKPOINT inhibitors represent a giant step forward in the treatment of many cancers, and as these agents have “come of age” in the past few years, so has the collective understanding of their potential for causing adverse events. Although checkpoint inhibitors are known to be associated...
No Improvement in Survival Reported With Epacadostat Plus Pembrolizumab in Advanced Melanoma
IN PATIENTS with unresectable or metastatic melanoma, adding epacadostat to pembrolizumab (Keytruda) did not result in greater clinical benefit over pembrolizumab alone, according to data from the phase III ECHO-301/KEYNOTE-252 study. These results were originally presented at the 2018 ASCO Annual...
Recent Drug Approvals and Revisions in Prescribing Information
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) issued the following approvals and prescribing information revisions in August 2018. Lenvatinib Approved for Unresectable Hepatocellular Carcinoma THE FDA approved lenvatinib (Lenvima) for the first-line treatment of patients with unresectable...
Adding Nimotuzumab to Chemoradiation Improved Survival in Locally Advanced Head and Neck Cancer
IN PATIENTS with locally advanced squamous cell carcinoma of the head and neck, nimotuzumab—a humanized monoclonal antibody against the epidermal growth factor receptor—in combination with cisplatin and radiotherapy was superior to cisplatin and radiotherapy alone in improving progression-free...
FDA Approves First Nonchemotherapy Combination Regimen for Patients With Waldenström’s Macroglobulinemia
ON AUGUST 27, 2018, the U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) for patients with Waldenström’s macroglobulinemia. The recent approval expands the label for ibrutinib in Waldenström’s macroglobulinemia beyond its current...
Clarifying the Complexity of Genomic Testing in Non-Hodgkin Lymphoma
AS MORE is learned about the genomic landscape in non-Hodgkin lymphoma, clinicians are grappling with how to apply this information in the clinic. At the 2018 Pan Pacific Lymphoma Conference, Andrew D. Zelenetz, MD, PhD, helped them understand this emerging area.1 Dr. Zelenetz is Professor of...
Relapsed or Refractory Hodgkin Lymphoma: Optimizing Salvage Therapy
As novel therapies come on board for treating relapsed or refractory Hodgkin lymphoma, the field is advancing toward more personalized therapy. The goal, even in the advanced-disease setting, is to increase the chances of complete response and negative positron-emission tomography (PET), while...
Proteomics May Be Used to Predict Treatment Outcomes in Triple-Negative Breast Cancer
In triple-negative breast cancer, researchers have so far been unable to identify markers that can classify patients by prognosis or probability of responding to different treatments. In a study published by Zagorac et al in Nature Communications, researchers from the Spanish National Cancer...
FDA Grants Breakthrough Therapy Designation to LOXO-292 for Treatment of Lung and Thyroid Cancers
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to LOXO-292, a selective RET inhibitor, for: the treatment of patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) who require systemic therapy and have had...
Over 130 Buildings and Landmarks in the United States and Canada to Be Illuminated in Support of Stand Up To Cancer's 6th Live Telecast
More than 130 iconic buildings and landmarks across the United States and Canada will be illuminated in a show of support for the 6th biennial Stand Up To Cancer (SU2C) “roadblock” telecast airing in both countries on Friday, September 7 (8:00–9:00 PM ...
Factors in Endocrine Deficiency in Pediatric and Young Adult Patients Receiving Radiotherapy for Brain Tumors
In a study reported in the Journal of Clinical Oncology, Vatner et al identified factors associated with an increased risk of endocrine deficiency in pediatric and young adult patients receiving radiation therapy for brain tumors, including hypothalamus and pituitary radiation dose. Study Details ...
Immune Checkpoint Inhibitors in Patients With HIV-Associated Kaposi Sarcoma
Widespread use of antiretroviral therapy in the treatment of patients infected with human immunodeficiency virus (HIV) has led to a decline in the incidence of HIV-related Kaposi sarcoma, an incurable malignancy associated with HIV. Nevertheless, about 15% of these patients will go on to...
Oncology Organizations Remember Senator John McCain
U.S. Senator from Arizona John McCain passed away on August 25, 2018. The cause of death was glioblastoma multiforme. A number of medical societies issued statements remembering Senator McCain, a few of which are reprinted below. The ASCO Post shares in remembering Senator McCain for his service to ...
Prostate Cancer Foundation and Movember Foundation Announce 2018 Winners of Challenge Awards
The Prostate Cancer Foundation (PCF) and the Movember Foundation recently announced four new Movember Foundation–PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the...
Every Day Is a Bonus
I have always been plagued with nagging headaches, so when they intensified in late 2010, I wasn’t too concerned. But when my eyes began involuntarily moving rapidly back and forth as I was writing Christmas cards, I knew the symptoms were a sign of something serious. A magnetic resonance imaging...
Outcomes After Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
In an interim analysis of a European trial reported in The Lancet Oncology, Francois-Xavier Mahon, MD, of Institut Bergonié, Bordeaux, and colleagues found that discontinuation of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (CML) with deep molecular response was...
PDL1 Amplification in Solid Tumors
In a study reported in JAMA Oncology, Aaron M. Goodman, MD, of the University of California, San Diego Moores Center for Personalized Cancer Therapy, and colleagues found amplification of PDL1 genes in 0.7% of solid tumors, including more than 100 tumor types. Response to checkpoint inhibition was ...
Treating Nonmetastatic Castration-Resistant Prostate Cancer: Implications of the PROSPER Trial
A MAN in his early 70s sits in our office. His general health is good, and he is feeling well. Yet he is deeply worried. Four years ago, when his prostate-specific antigen (PSA) level rapidly increased after radical prostatectomy and subsequent radiation therapy, he was started on...
